Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gert Ossenkoppele

Showing results (11-20 of 56) with videos related to

Pageof 6
Sort By:
Best Practice & Research. Clinical Haematology|June 18, 2019
Can we incorporate MRD assessment into clinical practice in AML?Gert Ossenkoppele, Gerrit Jan Schuurhuis, Arjan van de Loosdrecht, et al.
Pathology|December 30, 2019
Re: Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypesDiana Hanekamp, Costa Bachas, Arjan van de Loosdrecht, et al.
Blood Reviews|April 9, 2021
AML and the art of remission maintenanceMarcos de Lima, Gail J Roboz, Uwe Platzbecker, et al.
Amino Acids|January 4, 2014
Positioning of aminopeptidase inhibitors in next generation cancer therapySarina M Hitzerd, Sue Ellen Verbrugge, Gert Ossenkoppele, et al.
Leukemia|September 28, 2021
Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both?Shenmiao Yang, Neil E Kay, Min Shi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 27, 2009
Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AMLMonique Terwijn, Nicole Feller, Anna van Rhenen, et al.
Expert Review of Anticancer Therapy|January 28, 2015
Targeted therapy of acute myeloid leukemiaBenedito A Carneiro, Jessica K Altman, Jason B Kaplan, et al.
Haematologica|May 25, 2011
Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITDHendrik J M de Jonge, Peter J M Valk, Eveline S J M de Bont, et al.
Haematologica|November 22, 2011
Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia GroupFrédéric Baron, Stefan Suciu, Sergio Amadori, et al.
Blood|March 24, 2012
The EUTOS CML score aims to support clinical decision-makingVerena Hoffmann, Michele Baccarani, Joerg Hasford, et al.
Pageof 6

Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
Best Practice & Research. Clinical Haematology|June 18, 2019
Can we incorporate MRD assessment into clinical practice in AML?Gert Ossenkoppele, Gerrit Jan Schuurhuis, Arjan van de Loosdrecht, et al.
Pathology|December 30, 2019
Re: Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypesDiana Hanekamp, Costa Bachas, Arjan van de Loosdrecht, et al.
Blood Reviews|April 9, 2021
AML and the art of remission maintenanceMarcos de Lima, Gail J Roboz, Uwe Platzbecker, et al.
Amino Acids|January 4, 2014
Positioning of aminopeptidase inhibitors in next generation cancer therapySarina M Hitzerd, Sue Ellen Verbrugge, Gert Ossenkoppele, et al.
Leukemia|September 28, 2021
Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both?Shenmiao Yang, Neil E Kay, Min Shi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 27, 2009
Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AMLMonique Terwijn, Nicole Feller, Anna van Rhenen, et al.
Expert Review of Anticancer Therapy|January 28, 2015
Targeted therapy of acute myeloid leukemiaBenedito A Carneiro, Jessica K Altman, Jason B Kaplan, et al.
Haematologica|May 25, 2011
Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITDHendrik J M de Jonge, Peter J M Valk, Eveline S J M de Bont, et al.
Haematologica|November 22, 2011
Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia GroupFrédéric Baron, Stefan Suciu, Sergio Amadori, et al.
Blood|March 24, 2012
The EUTOS CML score aims to support clinical decision-makingVerena Hoffmann, Michele Baccarani, Joerg Hasford, et al.
Pageof 6